TABLE 2.
Targeted integration frequency
| Genotype | No. of targeted clones/no. of clones analyzed (% of targeting frequency)a
|
||
|---|---|---|---|
| OVALBUMIN | Ig Vλ | CENP-H | |
| Wild type | 44/50 (88.0) | 10/24 (41.7)b | 56/72 (77.8)c |
| RAD9−/− | 16/44 (36.3) | 5/16 (31.2) | |
| RAD17−/− | 19/44 (43.2) | 10/36 (27.7) | 9/16 (56.2) |
| PCNAK164R | 30/48 (62.5) | 21/38 (55) | |
a
Cell lines were transfected with targeting constructs for the indicated loci. Data shown are the number of targeted clones divided by the number of drug-resistant clones analyzed. Note that the PCNAK164R genotype is PCNAK164R/K164R/AID−/−/rAID/v-myb/ψV−.
b
Data from reference 46.
c
Data from reference 20.